Update on biomarkers for amyloid pathology in Alzheimer's disease

Nicholas J. Ashton*, Michael Schöll, Kerstin Heurling, Eleni Gkanatsiou, Erik Portelius, Kina Höglund, Gunnar Brinkmalm, Abdul Hye, Kaj Blennow, Henrik Zetterberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)


At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology. Furthermore, we will explore the current application of blood-based markers to assess Aβ pathology.

Original languageEnglish
Pages (from-to)799-812
Number of pages14
JournalBiomarkers in Medicine
Issue number7
Early online date15 Jun 2018
Publication statusPublished - Jul 2018


  • Alzheimer's disease
  • amyloid-β
  • biomarkers
  • blood-based biomarkers
  • cerebrospinal fluid
  • dementia
  • positron emission tomography


Dive into the research topics of 'Update on biomarkers for amyloid pathology in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this